BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 2,000 Shares of Stock

Posted by Francis Steltz on Aug 4th, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total value of $160,120.00. Following the sale, the chief accounting officer owned 127,401 shares of the company’s stock, valued at approximately $10,199,724.06. The trade was a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO opened at $79.96 on Tuesday. The stock has a market capitalization of $15.63 billion, a P/E ratio of -21.38 and a beta of 0.96. The stock’s fifty day moving average is $74.44 and its 200 day moving average is $72.80. BridgeBio Pharma, Inc. has a 52 week low of $42.09 and a 52 week high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million for the quarter, compared to analyst estimates of $178.07 million. The firm’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same period last year, the company earned ($0.88) earnings per share. Equities research analysts forecast that BridgeBio Pharma, Inc. will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd bought a new position in BridgeBio Pharma in the 3rd quarter valued at approximately $34,000. Jones Financial Companies Lllp bought a new stake in shares of BridgeBio Pharma during the first quarter worth $35,000. Farther Finance Advisors LLC grew its stake in shares of BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after buying an additional 372 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of BridgeBio Pharma during the fourth quarter worth $41,000. 99.85% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BBIO shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a report on Friday, May 15th. Mizuho lowered their price objective on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a research report on Tuesday, June 16th. Citigroup upped their target price on BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research note on Thursday, July 16th. Truist Financial raised their target price on BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Canaccord Genuity Group assumed coverage on BridgeBio Pharma in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price target on the stock. Twenty investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and an average target price of $95.21.

View Our Latest Research Report on BBIO

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.